国际妇产科学杂志

国际妇产科学杂志 ›› 2020, Vol. 47 ›› Issue (3): 345-349.

• 论著 • 上一篇    下一篇

基于Oncomine和TCGA数据库探究TOP2A在卵巢癌中的表达及意义#br#

张凯，刘玉林，胡佳丽，郭飞，薛凤霞   

  1. 300052  天津医科大学总医院妇产科
  • 收稿日期:2019-10-29 修回日期:2019-11-16 出版日期:2020-06-15 发布日期:2020-06-23
  • 通讯作者: 薛凤霞，E-mail：fengxiaxue1962@gmail.com E-mail:fengxiaxue1962@gmail.com
  • 基金资助:
    国家自然科学基金项目（81602292，81802617，81972448）；天津市自然科学基金项目（18JCQNJC81200）

Expression and Prognostic of TOP2A in Ovarian Cancer: An Analysis Based on the Data-Mining of Oncomine and TCGA Databases

ZHANG Kai, LIU Yu-lin, HU Jia-li, GUO Fei, XUE Feng-xia   

  1. Department of Obstetrics and Gynecology, Tianjin Medical Univercity General Hospital, Tianjin 300052, China
  • Received:2019-10-29 Revised:2019-11-16 Published:2020-06-15 Online:2020-06-23
  • Contact: XUE Feng-xia, E-mail：fengxiaxue1962@gmail.com E-mail:fengxiaxue1962@gmail.com

PDF (PC)

7110

摘要： 目的：探究拓扑异构酶ⅡA（TOP2A）在卵巢癌中的表达，预测分析TOP2A在卵巢癌发生、发展中的可能机制及临床意义。方法：利用Oncomine数据库中关于卵巢癌组织中TOP2A基因的相关信息和cBioPortal在线平台分析癌症和肿瘤基因图谱（Cancer Genome Atlas，TCGA）数据库中突变情况，并利用Kaplan-Meier Plotter进行生存分析。结果：纳入TOP2A相关性研究结果共462项，其中TOP2A表达具有差异的有132项，包括高表达125项，低表达7项；与对照组（正常卵巢组织）相比，卵巢癌组织中TOP2A的表达量要更高（P＜0.05）。311例上皮性卵巢癌样本中有12例发生TOP2A基因变异，突变率为4%，主要包括扩增3例，深度缺失3例，截短突变3例。与TOP2A基因主要相关的蛋白有DLGAP5、CDC20、UBE2C等10个。Kaplan-Meier生存分析显示TOP2A高表达的卵巢癌患者的总体生存时间和无瘤进展时间明显短于TOP2A低表达者，预后更差（P＜0.05）。结论：TOP2A在卵巢癌组织中高表达，且与卵巢癌患者的预后相关，为TOP2A作为肿瘤治疗的新靶点提供依据，也为卵巢癌的治疗提供新的方向。

关键词: 卵巢肿瘤；, Oncomine；, 肿瘤基因图谱数据库；, 拓扑异构酶ⅡA；, 生存分析

Abstract: Objective: To explore the topoisomerase ⅡA (TOP2A) expression in ovarian cancer and a forecast analysis TOP2A in its possible mechanism and clinical significance in the development of ovarian cancer. Methods: Data on TOP2A gene expression in ovarian cancer tissues were extracted from the Oncomine database. cBioPortal online platform were used to analyze the mutations in TCGA database, and then survival analysis of TOP2A were retrieved from the Kaplan-Meier Plotter tool. Results: A total of 462 TOP2A correlation studies were included, among which 132 showed statistically differences in TOP2A expression, including 125 up-regulated expression and 7 down-regulated expression. Compared with the control group, TOP2A expression in ovarian cancer tissues was higher than that in normal tissues (P＜0.05). TOP2A gene mutation occurred in 12 of 311 epithelial ovarian cancer samples, with a mutation rate of 4%, including amplification in 3 cases, deep loss in 3 cases and truncated mutation occurred in 3 patients. There were 10 proteins related to TOP2A gene, such as DLGAP5, CDC20 and UBE2C. Kaplan-Meier survival analysis showed that the overall survival time and progression-free survival time of ovarian cancer patients with high TOP2A expression were significantly shorter than those with low TOP2A expression (P＜0.05). Conclusions: TOP2A is highly expressed in ovarian cancer and is related to the prognosis of ovarian cancer patients, which might provide a new basis for TOP2A as a novel target for cancer therapy and a new direction for the treatment of ovarian cancer.

Key words: Ovarian neoplasms；, Oncomine；, Cancer genome atlas database；, Topoisomerase ⅡA ；, Survival analysis